Semaglutide vs Tirzepatide: Choosing the Right GLP-1 for Weight Loss
Two GLP-1 Pathways, One Decision
If you are weighing GLP-1 therapy for weight loss in Ann Arbor, the conversation usually narrows to two medications: semaglutide and tirzepatide. Both are injectable, both require a prescription, and both have large clinical trials behind them. The difference is in how each molecule works, how much weight patients tend to lose, and how each one feels week to week.
This guide compares the two side by side so you can walk into your first visit with clear questions rather than guesswork.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut releases after eating, which slows gastric emptying, reduces appetite, and tells the brain you are full sooner. The weekly injection keeps levels steady between doses.
The STEP clinical trial programme enrolled more than 10,000 participants across multiple studies. In STEP 1 (2021, New England Journal of Medicine), participants receiving semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks compared with 2.4% in the placebo group. Improvements in waist circumference, blood pressure, and HbA1c were also documented.
The SELECT cardiovascular outcomes trial (2023) showed a 20% reduction in major adverse cardiovascular events in overweight or obese adults without diabetes, establishing a benefit beyond the scale.
How Tirzepatide Works
Tirzepatide is a dual GIP and GLP-1 receptor agonist. In addition to acting on the GLP-1 pathway, it also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor. The dual action may enhance satiety signals and improve insulin sensitivity through a mechanism distinct from GLP-1 alone.
The SURMOUNT trial programme studied tirzepatide in adults with obesity or overweight. In SURMOUNT-1 (2022, New England Journal of Medicine), participants receiving the highest dose (15 mg weekly) lost an average of 22.5% of body weight over 72 weeks compared with 2.4% in the placebo group. Even at the lowest study dose (5 mg), mean weight loss reached 15%.
SURMOUNT-2, which focused on adults with type 2 diabetes, showed weight loss of up to 14.7% alongside meaningful HbA1c improvements.
Head-to-Head: What the Numbers Show
No large randomised head-to-head trial comparing semaglutide and tirzepatide at their full approved doses for weight management has been published as of early 2026. However, indirect comparison across the STEP and SURMOUNT trials provides a useful frame:
- Average body-weight reduction: Semaglutide 2.4 mg produced roughly 15% loss; tirzepatide 15 mg produced roughly 22% loss over similar timeframes.
- Participants achieving 20%+ loss: About 32% with semaglutide 2.4 mg; about 57% with tirzepatide 15 mg.
- Time to plateau: Both medications show the majority of weight loss within the first 60 to 72 weeks, with a plateau phase thereafter.
- Cardiovascular outcomes: Semaglutide has dedicated cardiovascular data from SELECT. Tirzepatide cardiovascular outcome data (SURPASS-CVOT) is expected but not yet published.
These figures come from different trial populations, so direct comparison has limits. Your clinician can help you interpret how these results apply to your health profile, your lab work, and your goals.
Side Effects: What Patients Report
Both medications share a similar side-effect profile because they act on overlapping pathways. The most common reports in both trial programmes:
- Nausea: The most frequently reported side effect for both. It tends to be most noticeable during the initial dose-titration weeks and usually eases as the body adjusts.
- Constipation or diarrhoea: Gastrointestinal changes are common early on. Adequate hydration and fibre often help.
- Decreased appetite: This is the intended mechanism rather than a side effect, but some patients find it more pronounced than expected.
- Injection-site reactions: Mild redness or irritation at the injection site. Rotating injection locations minimises this.
Discontinuation rates due to adverse events were broadly similar across both trial programmes (roughly 4% to 7%). Slow dose titration, which we follow at Arbour Longevity, helps most patients manage early GI symptoms.
Who Is a Candidate
At Arbour Longevity in Ann Arbor, every weight-loss plan starts with labs and a clinical assessment before any medication is considered. GLP-1 therapy may be appropriate if you have a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health concern such as elevated blood pressure, insulin resistance, or dyslipidaemia.
Certain conditions may make one medication more suitable than the other. If you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, GLP-1 receptor agonists are not appropriate. A thorough medical history and baseline labs are the first step.
Cost at Arbour Longevity
Medical weight loss at Arbour Longevity costs $299 to $599 per month, medication included. That covers the prescription, lab monitoring, and health coaching. The first visit is $35 and includes your baseline labs, a body-composition analysis, and a conversation with your clinician about which path fits your situation.
We disclose pricing upfront because cost should not be a surprise halfway through treatment. Membership plans (Silver, Gold, VIP) bundle monitoring visits and may lower the per-month cost if you are also pursuing other services.
How We Monitor Progress
A prescription without monitoring is not a plan. At Arbour, you receive:
- Baseline labs (metabolic panel, lipid panel, HbA1c, thyroid function, liver and kidney markers)
- Body-composition tracking at regular intervals
- Follow-up labs at 8 to 12 weeks and then quarterly
- Health coaching integrated into your visits, not outsourced to a separate app
If your labs or symptoms suggest a dose change, we adjust the plan rather than defaulting to a higher dose.
Making the Decision
Choosing between semaglutide and tirzepatide is a clinical conversation, not a marketing one. The right choice depends on your lab work, your medical history, how your body responds during titration, and what cardiovascular or metabolic concerns your clinician wants to address alongside weight loss.
Some patients start with one and switch to the other based on tolerability or response. That flexibility is part of a supervised programme. The goal is sustainable progress grounded in data, not a race to a number on the scale.
Next Step
If you are considering GLP-1 therapy in Ann Arbor, book a $35 first visit at Arbour Longevity. We will review your labs, discuss your history, and outline a plan before any prescription is written. No commitment beyond that first conversation.
Gandhi Bhattarai, FNP-BC, PMHNP-BC, AAOPM-certified in Anti-Aging/Functional Medicine
Nurse practitioner and founder of Arbour Longevity in Ann Arbor. Every article is written from clinic practice and reviewed against current guidelines.
✓ Medically reviewed · Last updated November 10, 2026
How we reviewed this article
Arbour Longevity articles are written by the treating clinician, checked against primary sources (peer-reviewed journals, FDA labeling, Endocrine Society and other specialty guidelines) and re-reviewed when guidance changes. See our editorial policy. Spotted an error? Email info@arbourlongevity.com.
This article is educational and is not a substitute for individualized medical advice. Whether a treatment is appropriate for you is determined during consultation.
Your symptoms have a cause. Let’s find it.
Book a $35 first visit in Ann Arbor. It’s a 30-minute consultation with Gandhi Bhattarai, applied toward your plan. Serving Ann Arbor, Ypsilanti, Saline, Dexter, Chelsea, and Michigan by telehealth.




.webp)

